Article

High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanoma

2025-05-15

Abstract excerpt

<title>Abstract</title> Background Despite significant advances in targeted (BRAFi + MEKi) and immune (anti-PD1/PD-L1, anti-CTLA4, and anti-LAG3) therapies, treatment options for NRASmut melanoma remain limited. Currently, NRASmut patients rely on immune checkpoint inhibitors, classical chemotherapy, and off-label MEK inhibitors, with over 50% experiencing rapid disease progression. One...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2cf7f727-88ae-5561-9c82-5dc3aece86f3
DOI: 10.21203/rs.3.rs-6594118/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanomaDOI 10.21203/rs.3.rs-6594118/v1Read

Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma.Semantic proximity Read

Beyond BRAF: where next for melanoma therapy?Semantic proximity Read

Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.Semantic proximity Read

Emerging targeted therapies for melanoma.Semantic proximity Read

B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant MelanomaSemantic proximity Read

Targeted Therapy Innovations for Melanoma.Semantic proximity Read

Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.Semantic proximity Read

Development of Personalized Strategies for Precisely Battling Malignant Melanoma.Semantic proximity Read

Characterization of Uveal Melanoma Cell Lines and Primary Tumor Samples in 3D CultureSemantic proximity Read

Metabolism-oriented compound screen in physiological culture conditions identifies a NAMPT inhibitor highly effective against drug-naïve and -resistant melanoma cellsSemantic proximity Read

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of MelanomaSemantic proximity Read

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read